Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. NICE technology appraisal guidance 178
National Institute for Health and Care Excellence (NICE)
Record ID 32018013396
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta178
Year Published:
2009
URL for published report:
https://www.nice.org.uk/guidance/ta178
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Bevacizumab
- Sorafenib
- Sunitinib
- Sirolimus
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.